U. Sancken
Institut für Humangenetik
Universität Göttingen
Deutschland
Name/email consistency: high
- Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin (hCG) or its free beta-subunit (free beta hCG). Sancken, U., Bahner, D. Fetal. Diagn. Ther. (2003)
- Preliminary data on an association between blood groups and serum markers used for the so-called "triple screening": free oestriol MoM values are decreased in rhesus-negative (Rh-) women. Sancken, U., Bartels, I. Prenat. Diagn. (2001)
- Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?. Sancken, U., Bartels, I. Prenat. Diagn. (2001)
- A retrospective evaluation of second-trimester serum screening for fetal trisomy 18: experience of two laboratories. Sancken, U., Bartels, I., Louwen, F., Eiben, B. Prenat. Diagn. (1999)